Form 4: Tivic Health CFO Granted 80,000 Stock Options

Tivic Health Systems' Chief Financial Officer, Lisa G. Wolf, was granted 80,000 employee stock options with a four-year vesting schedule.

Summary

• Lisa G. Wolf, Chief Financial Officer of Tivic Health Systems, Inc. (TIVC), was granted 80,000 employee stock options.
• The options have an exercise price of $3.32 per share.
• The grant date for these options was August 6, 2025, with an expiration date of August 5, 2035.
• The vesting schedule for the stock options is as follows: 50% vests upon the first anniversary of the grant date, and the remaining 50% vests in twelve successive equal quarterly installments from the first anniversary, leading to 100% vesting upon the fourth anniversary of the grant date.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, as it details a standard executive compensation event that aligns management incentives with shareholder interests, without indicating any immediate financial performance changes or significant strategic shifts.

Positives

• The stock option grant aligns the Chief Financial Officer's incentives with shareholder interests, encouraging long-term performance and value creation.
• This grant serves as a retention mechanism for key executive talent within the company.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders.

Risks

• The value of the stock options is contingent on the future market price of Tivic Health Systems' common stock exceeding the exercise price of $3.32.
• The options are subject to a multi-year vesting schedule, meaning the recipient must remain with the company for the options to fully vest.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's stock option grant.

Industry Context

The granting of stock options to key executives is a common practice across various industries, particularly in technology and healthcare, to incentivize performance and align management interests with those of shareholders. This specific grant is a routine compensation disclosure for an executive.

Comparison to Industry Standards

• The vesting schedule of 50% after one year and quarterly thereafter for a total of four years is a standard industry practice for executive stock option grants, comparable to those seen at companies like Medtronic (MDT) or Boston Scientific (BSX) for similar executive roles, aiming for long-term retention and performance alignment.
• An exercise price of $3.32, likely based on the market price at the time of grant, is typical for employee stock options, ensuring they are 'at-the-money' upon issuance.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize strong company performance.
• Employees: This grant may signal the company's commitment to executive retention and performance-based compensation, potentially influencing broader compensation strategies.

Next Steps

• The stock options will vest according to the specified schedule over the next four years, contingent on the CFO's continued employment.

Key Dates

Keywords

Tivic Health Systems, TIVC, Stock Options, Employee Stock Option, CFO, Lisa G. Wolf, Executive Compensation, SEC Form 4, Insider Transaction, Vesting Schedule